Guinea pig cytomegalovirus: A model for the prevention and treatment of maternal-fetal cytomegalovirus transmission

Future Virology

Volumn 5, Issue 2, 2010, Pages 207-217

  Schleiss, Mark R ^a   McVoy, Michael A ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral therapy; Congenital cytomegalovirus infection; Cytomegalovirus immune globulin; Cytomegalovirus vaccines; Glycoprotein B vaccine; Guinea pig cytomegalovirus; Live attenuated vaccine; Neutralizing antibodies; Pp65 vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DNA VACCINE; NEUTRALIZING ANTIBODY;

CYTOMEGALOVIRUS INFECTION; GUINEA PIG; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MOLECULAR BIOLOGY; MOLECULAR CLONING; MOTHER FETUS RELATIONSHIP; NEWBORN INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SEQUENCE HOMOLOGY; VERTICAL TRANSMISSION; VIRAL GENETICS; VIRAL TROPISM; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS TRANSMISSION;

EID: 77649277640     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.8     Document Type: Review

References (90)

1. Malm G, Engman ML: Congenital cytomegalovirus infections. Semin. Fetal Neonatal Med. 12, 154-159 (2007).
2. Cheeran MCJ, Lokensgard JR, Schleiss MR: Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin. Microbiol. Rev. 22, 1-28 (2009).
3. Pass RF: Congenital cytomegalovirus infection and hearing loss. Herpes 12, 50-55 (2005).
4. Fowler KB, Boppana SB: Congenital cytomegalovirus (CMV) infection and hearing deficit. J. Clin. Virol. 35, 226-231 (2006).
5. Nance WE, Lim BG, Dodson KM: Importance of congenital cytomegalovirus infections as a cause for pre-lingual hearing loss. J. Clin. Virol. 35, 221-225 (2006).
6. Lazzarotto T, Varani S, Spezzacatena P et al.: Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus. Viral Immunol. 13, 137-141 (2000).
7. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA: The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326, 663-667 (1992).
8. Fowler KB, Stagno S, Pass RF: Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289, 1008-1011 (2003).
9. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee: Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin. Infect. Dis. 39, 233-239 (2004).
10. Griffiths PD, McLean A, Emery VC: Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 19, 1356-1362 (2001).
11. Zhong J, Khanna R: Vaccine strategies against human cytomegalovirus infection. Expert Rev. Anti. Infect. Ther. 5, 449-459 (2007).
12. Adler SP: Human CMV vaccine trials: what if CMV caused a rash? J. Clin. Virol. 41, 231-236 (2008).
13. Pass RF, Zhang C, Evans A et al.: Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360, 1191-1199 (2009).
14. Schleiss MR: Cytomegalovirus vaccine development. Curr. Top. Microbiol. Immunol. 325, 361-382 (2008).
15. Murphy E, Shenk T: Human cytomegalovirus genome. Curr. Top. Microbiol. Immunol. 325, 1-19 (2008).
16. Söderberg-Nauclér C: Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med. 259, 219-246 (2006).
17. Kern ER: Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res. 71, 164-171 (2006).
18. Hartley JW, Rowe WP, Huebner RJ: Serial propagation of the guinea pig salivary gland virus in tissue culture. Proc. Soc. Exp. Biol. Med. 96, 281-285 (1957).
19. Middelkamp JN, Patrizi G, Reed CA: Light and electron microscopy studies of the guinea pig cytomegalovirus. J. Ultrastruct. Res. 18, 85-101 (1967).
20. Fong CK, Bia F, Hsiung GD: Ultrastructural development and persistence of guinea pig cytomegalovirus in duet cells of guinea pig submaxillary gland. Arch. Virol. 64, 97-108 (1980).
21. Fong CK, Lucia H, Bia FJ, Hsiung GD: Histopathologic and ultrastructural studies of disseminated cytomegalovirus infection in strain 2 guinea pigs. Lab. Invest. 49, 183-194 (1983).
22. Bia FJ, Summers WC, Fong CK, Hsuing GD: New endogenous herpesvirus of guinea pigs, biological and molecular characterization. J. Virol. 36, 245-253 (1980).
23. Isom HC, Gao M, Wigdahl B: Characterization of guinea pig cytomegalovirus DNA. J. Virol. 49, 426-436 (1984).
24. Gao M, Isom HC: Characterization of the guinea pig cytomegalovirus genome by molecular cloning and physical mapping. J. Virol. 52, 436-447 (1984).
25. Schleiss MR: Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV). J. Clin. Virol. 25(Suppl. 2), S37-S49 (2002).
26. Schleiss MR, McGregor A, Choi KY, Date SV, Cui X, McVoy MA: Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome. Virol. J. 5, 139 (2008).
27. McGregor A, Schleiss MR: Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli. Mol. Genet. Metab. 72, 15-26 (2001).
28. Cui X, McGregor A, Schleiss MR, McVoy MA: Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. J. Virol. Methods 149, 231-239 (2008).
29. Schleiss MR: Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J. 47, 65-72 (2006).
30. Hsuing GD, Choi YC, Bia F: Cytomegalovirus infection in guinea pigs. I. Viremia during acute primary and chronic persistent infection. J. Infect. Dis. 138, 191-196 (1978).
31. Griffith BP, Lucia HL, Bia FJ, Hsuing GD: Cytomegalovirus-induced mononucleosis in guinea pigs. Infect. Immun. 32, 857-863 (1981).
32. Bia FJ, Lucia HL, Fong CK, Tarsio M, Hsuing GD: Effects of vaccination on cytomegalovirus-associated interstitial pneumonia in strain 2 guinea pigs. J. Infect. Dis. 145, 742-747 (1982).
33. Aquino-de Jesus MJ, Griffith BP: Cytomegalovirus infection in immunocompromised guinea pigs, a model for testing antiviral agents in vivo. Antiviral Res. 12, 181-193 (1989).
34. Bourne N, Bravo FJ, Bernstein DI: Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. Antiviral Res. 47, 103-109 (2000).
35. Schleiss MR, Bernstein DI, McVoy MA et al.: The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res. 65, 35-43 (2005).
36. Booss J, Dann PR, Griffith BP, Kim JH: Glial nodule encephalitis in the guinea pig, serial observations following cytomegalovirus infection. Acta Neuropathol. 75, 465-473 (1988).
37. Keithley EM, Sharp P, Woolf NK, Harris JP: Temporal sequence of viral antigen expression in the cochlea induced by cytomegalovirus. Acta Otolaryngol. 106, 46-54 (1988).
38. Griffith BP, Lavallee JT, Jennings TA, Hsuing GD: Transmission of maternal cytomegalovirus-specific immunity in the guinea pig. Clin. Immunol. Immunopathol. 35, 169-181 (1985).
39. Zheng ZM, Lavallee JT, Bia FJ, Griffith BP: Thymic hypoplasia, splenomegaly and immune depression in guinea pigs with neonatal cytomegalovirus infection. Dev. Comp. Immunol. 11, 407-418 (1987).
40. Booss J, Dann PR, Griffith BP, Kim JH: Host defense response to cytomegalovirus in the central nervous system. Predominance of the monocyte. Am. J. Pathol. 134, 71-78 (1989).
41. Bravo FJ, Bourne N, Schleiss MR, Bernstein DI: An animal model of neonatal cytomegalovirus infection. Antiviral Res. 60, 41-49 (2003).
42. Bia FJ, Griffith BP, Fong CKY, Hsuing GD: Cytomegaloviral infections in the guinea pig, experimental models for human disease. Rev. Infect. Dis. 5, 177-195 (1983).
43. Enders AC: A comparative study of the fine structure of the trophoblast in several haemochorial placentas. Am. J. Anat. 116, 29-67 (1965).
44. Griffith BP, McCormick SR, Fong CKY et al.: The placenta as a site of cytomegalovirus infection in guinea pigs. J. Virol. 55, 402-409 (1985).
45. Medearis DN: Mouse cytomegalovirus infection. III. Attempts to produce intrauterine infections. Am. J. Hyg. 80, 113-120 (1964).
46. Choi YC, Hsuing GD: Cytomegalovirus infection in guinea pigs. II. Transplacental and horizontal transmission. J. Infect. Dis. 138, 197-202 (1978).
47. Kumar ML, Nankervis GA: Experimental congenital infection with cytomegalovirus, a guinea pig model. J. Infect. Dis. 138, 650-654 (1978).
48. Johnson KP, Connor WS: Guinea pig cytomegalovirus, transplacental transmission. J. Exp. Med. 59, 263-267 (1979).
49. Griffith BP, Lucia HL, Hsuing GD: Brain and visceral involvement during congenital cytomegalovirus infection of guinea pigs. Pediatr. Res. 16, 455-459 (1982).
50. Woolf NK, Koehrn FJ, Harris JP, Richman DD: Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs. J. Infect. Dis. 160, 929-937 (1989).
51. Katano H, Sato Y, Tsutsui Y et al.: Pathogenesis of cytomegalovirus-associated labyrinthitis in a guinea pig model. Microbes Infect. 9, 183-191 (2007).
52. Bia FJ, Griffith BP, Tarsio M, Hsuing GD: Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus. J. Infect. Dis. 142, 732-738 (1980).
53. Harrison CJ, Britt WJ, Chapman NM, Mullican J, Tracy S: Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J. Infect. Dis. 172, 1212-1220 (1995).
54. Bourne N, Schleiss MR, Bravo FJ, Bernstein DI: Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection. J. Infect. Dis. 183, 59-64 (2001).
55. Schleiss MR, Bourne N, Jensen NJ, Bravo F, Bernstein DI: Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83. Virol. Immunol. 13, 155-167 (2000).
56. Schleiss MR, Bourne N, Bernstein DI: Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J. Infect. Dis. 188, 1868-1874 (2003).
57. Schleiss MR, Lacayo JC, Belkaid Y et al.: Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis. 195, 789-789 (2007).
58. Schleiss MR, Jensen NJ: Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection. J. Virol. Methods 108, 59-65 (2003).
59. Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI: Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J. Infect. Dis. 189, 1374-1381 (2004).
60. Crumpler MM, Choi KY, McVoy MA, Schleiss MR: A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Vaccine 27, 4209-4218 (2009).
61. Haggerty SM, Schleiss MR: A novel CC-chemokine homolog encoded by guinea pig cytomegalovirus. Virus Genes 25, 271-279 (2002).
62. Penfold M, Miao Z, Wang Y, Haggerty S, Schleiss MR: A macrophage inflammatory protein homolog encoded by guinea pig cytomegalovirus signals via CC chemokine receptor 1. Virology 316, 202-212 (2003).
63. Schraff SA, Schleiss MR, Brown DK et al.: Macrophage inflammatory proteins in cytomegalovirus-related inner ear injury. Otolaryngol. Head Neck Surg. 137, 612-618 (2007).
64. Schraff SA, Brown DK, Schleiss MR, Meinzen-Derr J, Greinwald JH, Choo DI: The role of CMV inflammatory genes in hearing loss. Otol. Neurotol. 28, 964-969 (2007).
65. Hahn G, Revello MG, Patrone M et al.: Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78, 10023-10033 (2004).
66. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC: Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J. Virol. 80, 710-722 (2006).
67. Wang D, Shenk T: Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol. 79, 10330-10338 (2005).
68. Hahn G, Khan H, Baldanti F, Koszinowski UH, Revello MG, Gerna G: The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J. Virol. 76, 9551-9555 (2002).
69. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U: Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J. Gen. Virol. 87, 2451-2460 (2006).
70. Gerna G, Sarasini A, Patrone M et al.: Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol. 89, 853-865 (2008).
71. Wang D, Shenk T: Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl Acad. Sci. USA 102, 18153-18158 (2005).
72. Marshall GS, Rabalais GP, Stout GG, Waldeyer SL: Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis. 165, 381-384 (1992).
73. Pass RF: Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J. Clin. Virol. 46(Suppl. 4), S73-S76 (2009).
74. Cui X, Meza BP, Adler SP, McVoy MA: Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26, 5760-5766 (2008).
75. Lb́ region of wild-type rhesus cytomegalovirus. Virology 373, 181-188 (2008).
76. Lilja AE, Shenk T: Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types. Proc. Natl Acad. Sci. USA 105, 19950-19955 (2008).
77. Nozawa N, Yamamoto Y, Fukui Y et al.: Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture. Virology 379, 45-54 (2008).
78. Yamada S, Nozawa N, Katano H et al.: Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130. Virology 391, 99-106 (2009).
79. Ryckman BJ, Rainish BL, Chase MC et al.: Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 82, 60-70 (2008).
80. Bratcher DF, Bourne N, Bravo FJ et al.: Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J. Infect. Dis. 172, 944-950 (1995).
81. Chatterjee A, Harrison CJ, Britt WJ, Bewtra C: Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein B antibody transfer in guinea pigs. J. Infect. Dis. 183, 1547-1553 (2001).
82. Schleiss MR, Anderson JL, McGregor A: Cyclic cidofovir (cHPMPC) prevents congenital cytomegalovirus infection in a guinea pig model. Virol. J. 1(3), 9 (2006).
83. Bravo FJ, Cardin RD, Bernstein DI: Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis. 193, 591-597 (2006).
84. McGregor A, Choi KY, Cui X, McVoy MA, Schleiss MR: Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir. Antiviral Res. 78, 250-259 (2008).
85. Nigro G, Adler SP, La Torre R, Best AM; Congenital Cytomegalovirus Collaborating Group: Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 353, 1350-1362 (2005).
86. Griffiths PD: Strategies to prevent CMV infection in the neonate. Semin. Neonatol. 7, 293-299 (2002).
87. Jeon J, Victor M, Adler SP et al.: Knowledge and awareness of congenital cytomegalovirus among women. Infect. Dis. Obstet. Gynecol. 2006, 80383 (2006).
88. Ross DS, Dollard SC, Victor M, Sumartojo E, Cannon MJ: The epidemiology and prevention of congenital cytomegalovirus infection and disease: activities of the Centers for Disease Control and Prevention Workgroup. J. Womens Health (Larchmt) 15, 224-229 (2006).
89. Hakki M, Marshall EE, De Niro KL, Geballe AP: Binding and nuclear relocalization of protein kinase R by human cytomegalovirus TRS1. J. Virol. 80, 11817-11826 (2006).
90. Marshall EE, Geballe AP: Multifaceted evasion of the interferon response by cytomegalovirus. J. Interferon Cytokine Res. 29, 609-619 (2009).